Zenas BioPharma, Inc. Common Stock (ZBIO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $31.48 (-1.53%), Market cap $1.23B, 52-week low–high $9.14 ~ $43.17.
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed
Financial statements, price targets, institutional (13F) holdings and related news for Zenas BioPharma, Inc. Common Stock are updated in real time on BlackAll Trade.
Zenas BioPharma, Inc. Common Stock trades at $31.48 (-1.53%). Real-time quotes and charts are available on BlackAll Trade.
Zenas BioPharma, Inc. Common Stock has a market cap of about $1.23B.
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bi